ArticleNPJ digital medicine2025
A clinically validated 3D deep learning approach for quantifying vascular invasion in pancreatic cancer.
Article in NPJ digital medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From IBS to IBD? Strengthening causal inference and clinical translation in Song et al.Journal of gastroenterology · 2026Article
- Multiomics Analysis of Nucleotide Metabolism Highlights the Important Role of Adenylate Kinase 4 in Pancreatic Cancer.Human mutation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Vascular invasion assessment is critical for surgical planning in pancreatic ductal adenocarcinoma (PDAC). Current CT-based assessments often rely on radiologists' subjective 2D interpretations, which may not capture the continuous, three-dimensional tumor-vessel interactions and multiple vessel involvement, both essential for accurate preoperative evaluation. PAN-VIQ (Pancreatic Vascular Invasion Quantifier) is an automated deep learning framework to quantify tumor-vessel interactions from contrast-enhanced CT scans. It enables segmentation of pancreatic tumors and five critical vessels: celiac artery (CA), common hepatic artery (CHA), superior mesenteric artery (SMA), superior mesenteric vein (SMV), and portal vein (PV), quantifying vascular involvement through 3D encasement angles. PAN-VIQ was trained and internally validated on 2130 cases, and subsequently prospectively tested in 202 patients. External validation showed accuracies exceeding 90%. In prospective evaluation, the model outperformed junior radiologists and matched senior radiologists in accuracy and recall. These results underscore potential of PAN-VIQ to standardize vascular invasion assessment and reduce interobserver variability.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.